Form 4: Fibrogen CFO Reports Stock Transaction
Insider Transaction (Form 4)
David Delucia, Chief Financial Officer of Fibrogen Inc, reported a transaction in 22 shares of common stock on September 6, 2026.
Summary
- Tax/exercise-price withholding: disposed of 22 Common Stock at $8.55 ($188) on September 6, 2026; holds 4,355 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
David Delucia — Officer (Chief Financial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-06 | Tax/exercise-price withholding | Common Stock | 22 | $9 | $188 | 4,355 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-06 | Tax/exercise-price withholding (22 shares) |
Keywords
insider transaction, Form 4, KYNB, KYNTRA BIO, INC., neutral, David Delucia
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.